1. Home
  2. HBNC vs AKBA Comparison

HBNC vs AKBA Comparison

Compare HBNC & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Horizon Bancorp Inc.

HBNC

Horizon Bancorp Inc.

HOLD

Current Price

$16.48

Market Cap

883.5M

Sector

Finance

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.23

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBNC
AKBA
Founded
1873
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
883.5M
729.1M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
HBNC
AKBA
Price
$16.48
$1.23
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$20.33
$5.75
AVG Volume (30 Days)
343.9K
3.3M
Earning Date
03-30-2026
05-27-2026
Dividend Yield
3.79%
N/A
EPS Growth
25.00
93.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$51.78
$1.84
Revenue Next Year
$10.63
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.70
$1.14
52 Week High
$19.07
$4.08

Technical Indicators

Market Signals
Indicator
HBNC
AKBA
Relative Strength Index (RSI) 37.46 41.45
Support Level $15.74 $1.14
Resistance Level $16.58 $1.55
Average True Range (ATR) 0.57 0.08
MACD -0.15 0.01
Stochastic Oscillator 5.18 21.62

Price Performance

Historical Comparison
HBNC
AKBA

About HBNC Horizon Bancorp Inc.

Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: